• news.cision.com/
  • AcouSort/
  • AcouSort strengthens commercial offering with the release of new AcouWash application notes

AcouSort strengthens commercial offering with the release of new AcouWash application notes

Report this content

AcouSort releases new marketing material showing the superiority of the company’s technology compared to competitive techniques. With two new application notes on isolation of different blood components, the company further strengthens its commercial offering to customers in the Life Science industry and academia.

The new application notes show how AcouSort’s technology can improve advanced sample preparations by workflow automation for isolation of platelets and mononuclear cells (MNC) from whole blood. With AcouWash processing, a higher sample quality is achieved compared to conventional techniques in a far less labor intense way.  

– The release of the new AcouWash application notes and the upcoming launch of the next generation AcouWash system are important steps to strengthen our commercial offering. Our research systems AcouWash and AcouTrap allow researchers and Life Science companies to apply and evaluate our technology. And we know from experience that such evaluations are very important towards securing collaboration projects that could potentially lead to OEM deals. Therefore, our systems play a key role in our strategy to become the preferred provider of sample preparation components to the Life Science industry. With these latest results, we further broaden the range of applications for our acoustic separation technology, says AcouSort’s CEO Torsten Freltoft.

Isolation of platelets is of significant interest to enable studies of platelets as potential biomarker source for detection of diseases such as cancer and coagulation disorders, as well as for the development of platelet-based diagnostics. With the acoustic technology built into the AcouWash, isolation is simple, label-free, highly efficient and very gentle to the sensitive blood platelets.

Separation of mononuclear cells (MNCs) from whole blood is a key process step prior to many different research, diagnostic and therapeutic procedures. The standard density centrifugation method is time- and labor consuming, requires large sample volumes and is ill-suited for integration. With the AcouWash technology, the process is automated and generates high quality results with superior cell viability.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.


Documents & Links